Alkermes plc

Alkermes plc is a global biopharmaceutical company whose core business model involves the development of medicines that require animal testing for regulatory approval and safety assessment. As a developer of novel central nervous system (CNS) therapeutics, Alkermes conducts preclinical research that includes in vivo studies on animals. The company’s pipeline and marketed products, such as its extended-release injectable formulations, are advanced through stages of development that necessitate animal testing as a standard industry practice for biopharmaceutical firms. This reliance on animal models is integral to its drug development process.

The company’s corporate responsibility reports from 2023 to 2025 do not disclose a formal policy against animal testing, nor do they outline commitments to adopt or fund alternative non-animal testing methods. While the reports discuss environmental and social governance, they lack substantive detail on efforts to reduce or replace animal use in its research and development activities. The absence of such commitments indicates that animal testing remains a standard, unchallenged component of its operational model.